Novartis Acquires Regulus Therapeutics to Advance microRNA-Based Therapy for ADPKD
Novartis has announced its acquisition of Regulus Therapeutics in a transaction valued at up to $1.7 billion. This strategic move aims to advance farabursen, an investigational microRNA inhibitor targeting miR-17, for the treatment of autosomal dominant polycystic kidney disease (ADPKD), the most common genetic cause of renal failure.
Farabursen demonstrated promising safety and biomarker improvements in early clinical trials, including increased urinary polycystin levels and stable kidney volume. The program is on track for a Phase 3 trial starting in the third quarter of 2025, with hopes of achieving accelerated approval.
At baseclick, a leader in customized oligonucleotide synthesis and click chemistry, we recognize this milestone as an important signal of the growing momentum and success of RNA-targeted therapies. Developments like these underscore the vital role that high-quality nucleic acid tools and manufacturing play in the rapidly evolving RNA therapeutic landscape.
We look forward to supporting innovators with our proven expertise as RNA and microRNA-based therapies continue to transform the future of medicine.
⸻
🔗 Read the full press release:
Novartis Media Release